Data from the PREVAIL trial’s open-label extension demonstrated that gefurulimab sustained functional improvements in people with generalized myasthenia gravis for one year. Improvements were observed across several scales, including the Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Composite (MGC) scales. At one year, MG-ADL scores improved by 5.3 points, QMG scores improved by 5.3 points, and MGC scores were 9.4 points better. Improvements emerged for patients switching from placebo, with MG-ADL scores improving by 4.9 points, QMG scores improving by 4.6 points, and MGC scores improving by 8.3 points. The median treatment duration was 575 days, with a well-tolerated safety profile consistent with prior studies.
The phase III trial randomized 260 participants to receive weekly gefurulimab or placebo for 26 weeks. Improvements in MG-ADL and QMG scores occurred within one and four weeks, respectively, and were sustained through week 26. Common adverse events included injection site reactions, headache, back pain, and nasopharyngitis. Complement C5 inhibitors, including eculizumab, ravulizumab, and zilucoplan, are approved for myasthenia gravis.
Of the 249 patients completing the randomized controlled period, all entered the open-label extension. At the data cutoff in November 2025, 211 patients continued treatment. The European Medicines Agency recommended gefurulimab for EU approval, and the drug is under FDA review.